Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14665921 | 0.83 | HTR6 (0.45) | HTR6CYP2C19NPSR1CYP1A2CYP2C9 | |
| SCHEMBL19221916 | 0.81 | HTR6 (0.44) | HTR6CYP2C19NPSR1CYP1A2CYP2C9 | |
| SCHEMBL469930 | 0.81 | HTR6 (0.45) | HTR6CYP2C19NPSR1CYP1A2CYP2C9 | |
| SCHEMBL27856070 | 0.77 | HTR6 (0.41) | HTR6CYP2C19NPSR1CYP1A2CYP2C9 | |
| SCHEMBL458467 | 0.75 | HTR6 (0.43) | HTR6CYP2C19CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL28805323 | 0.73 | KMO (0.47) | HTR6CYP2C19NPSR1CYP1A2CYP2C9 | |
| SCHEMBL458128 | 0.71 | HTR6 (0.39) | HTR6CYP2C19NPSR1CYP1A2CYP2C9 | |
| SCHEMBL12450255 | 0.70 | HTR6 (0.45) | HTR6CYP2C19CYP1A2CYP2C9ALDH1A1 | |
| SCHEMBL111538 | 0.69 | KMT2A (0.39) | HTR6CYP2C19NPSR1CYP1A2CYP2C9 | |
| SCHEMBL110755 | 0.69 | HTR6 (0.39) | HTR6CYP2C19NPSR1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3260453-B1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2021-03-31 | — | — | EP | disclosed |
| US-10946025-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2021-03-16 | — | — | US | disclosed |
| US-20200206237-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2020-07-02 | — | — | US | disclosed |
| US-10624898-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2020-04-21 | — | — | US | disclosed |
| US-20190328744-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10383879-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20190175608-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2019-06-13 | — | — | US | disclosed |
| US-20180325911-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2018-11-15 | — | — | US | disclosed |
| EP-2632921-B1 | POLYMORPHS AND SALTS OF 6-(1H-INDOL-4-YL)-4-(5-{[4-(1-METHYLETHYL)-1-PIPERAZINYL]METHYL}-1,3-OXAZOL-2-YL)-1H-INDAZOLE AS PI3K INHIBITORS FOR USE IN THE TREATMENT OF E.G. RESPIRATORY DISORDERS | GLAXO GROUP LTD (GB) | 2018-10-17 | — | — | EP | disclosed |
| EP-3260453-A1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | Glaxo Group Limited (GB) | 2017-12-27 | — | — | EP | disclosed |
| US-20130203772-A1 | Polymorphs and Salts | GLAXO GROUP LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| US-20130165441-A1 | Novel Polymorphs and Salts | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130131080-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20130096117-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-04-18 | — | — | US | disclosed |
| US-20130029985-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| EP-2424864-A1 | OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS | Glaxo Group Limited (GB) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046286-A1 | Novel Compounds | HAMBLIN JULIE NICOLE (GB) | 2012-02-23 | — | — | US | disclosed |
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280045-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165441-A1 | Novel Polymorphs and Salts | PRKDC, PRKACA, MAP3K20 | HTR6 4166/4885CYP2C19 1206/4885NPSR1 3196/4885 |
| US-20130029985-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | HTR6 4373/4885CYP2C19 1453/4885NPSR1 2837/4885 |
| US-20130131080-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | HTR6 4373/4885CYP2C19 1453/4885NPSR1 2837/4885 |
| US-10624898-B2 | Compounds | PIK3CA, PIK3CD, PIK3C3 | HTR6 4089/4885CYP2C19 754/4885NPSR1 2131/4885 |
| US-10383879-B2 | Compounds | PIK3CA, PIK3CD, PIK3C3 | HTR6 4089/4885CYP2C19 754/4885NPSR1 2131/4885 |
| US-10946025-B2 | Compounds | PIK3CA, PIK3CD, PIK3C3 | HTR6 4089/4885CYP2C19 754/4885NPSR1 2131/4885 |
| US-20190328744-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | HTR6 4445/4885CYP2C19 1942/4885NPSR1 2317/4885 |
| US-20100280045-A1 | NOVEL COMPOUNDS | PLK3, PLK1, PLK2 | HTR6 3865/4885CYP2C19 4031/4885NPSR1 3968/4885 |
| US-20180325911-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | HTR6 4445/4885CYP2C19 1942/4885NPSR1 2317/4885 |
| US-20190175608-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | HTR6 4445/4885CYP2C19 1942/4885NPSR1 2317/4885 |
| US-20100280029-A1 | NOVEL COMPOUNDS | PIK3CD, PIK3CA, PIK3C2B | HTR6 4373/4885CYP2C19 1453/4885NPSR1 2837/4885 |
| US-20130203772-A1 | Polymorphs and Salts | PRKDC, PRKACA, MAP3K6 | HTR6 4164/4885CYP2C19 934/4885NPSR1 3294/4885 |
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | HTR6 1564/4885CYP2C19 2386/4885NPSR1 160/4885 |
| US-20120046286-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | HTR6 4373/4885CYP2C19 1453/4885NPSR1 2837/4885 |
| US-20130096117-A1 | Novel Compounds | PIK3CD, PIK3CA, PIK3C2B | HTR6 4373/4885CYP2C19 1453/4885NPSR1 2837/4885 |
| US-20200206237-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | HTR6 4445/4885CYP2C19 1942/4885NPSR1 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.